Pfizer Plans Four New Products A Year Starting In 2011
This article was originally published in The Pink Sheet Daily
Executive Summary
Company highlights strength of pipeline at R&D briefing, but says it will rely on a near-term licensing strategy to address “gaps.”
You may also be interested in...
Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene
The pharma giant has 85 new molecular entities in development, with 99 total programs in Phase I through Phase III.
Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene
The pharma giant has 85 new molecular entities in development, with 99 total programs in Phase I through Phase III.
Pfizer Looks To Make Its Big Pharma Engine More Agile By Cutting 10,000
Company's reorganization will include R&D rationalization, manufacturing consolidation and European field force cuts.